Steve Scala
Stock Analyst at TD Cowen
(2.82)
# 1,643
Out of 5,241 analysts
33
Total ratings
74.07%
Success rate
14.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Scala
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Hold | $100 → $120 | $111.38 | +7.74% | 2 | Jan 20, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $42 → $45 | $52.85 | -14.85% | 2 | Dec 11, 2025 | |
| ABBV AbbVie | Maintains: Buy | $195 → $225 | $210.39 | +6.94% | 12 | Oct 7, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $59 | $57.00 | +3.51% | 3 | Oct 7, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $90 → $95 | $181.58 | -47.68% | 1 | Aug 12, 2024 | |
| PFE Pfizer | Downgrades: Market Perform | $32 | $25.33 | +26.33% | 1 | Jan 4, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $430 → $500 | $1,004.92 | -50.24% | 8 | May 23, 2023 | |
| NVS Novartis AG | Downgrades: Market Perform | $110 → $105 | $148.08 | -29.09% | 4 | Feb 1, 2021 |
Merck & Co.
Jan 20, 2026
Maintains: Hold
Price Target: $100 → $120
Current: $111.38
Upside: +7.74%
Royalty Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $42 → $45
Current: $52.85
Upside: -14.85%
AbbVie
Oct 7, 2024
Maintains: Buy
Price Target: $195 → $225
Current: $210.39
Upside: +6.94%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Hold
Price Target: $53 → $59
Current: $57.00
Upside: +3.51%
AstraZeneca
Aug 12, 2024
Maintains: Buy
Price Target: $90 → $95
Current: $181.58
Upside: -47.68%
Pfizer
Jan 4, 2024
Downgrades: Market Perform
Price Target: $32
Current: $25.33
Upside: +26.33%
Eli Lilly and Company
May 23, 2023
Maintains: Outperform
Price Target: $430 → $500
Current: $1,004.92
Upside: -50.24%
Novartis AG
Feb 1, 2021
Downgrades: Market Perform
Price Target: $110 → $105
Current: $148.08
Upside: -29.09%